Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population
Scandinavian Journal of Immunology · 2026-05 · 103 (5)
DOI: 10.1111/sji.70119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, online erschienen am 18.05.2026. Verfasst von Marta Kaminska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Protein-Arginine Deiminase Type 4, Anti-Citrullinated Protein Antibodies, Biomarkers. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Narodowe Centrum Nauki, Norges Forskningsråd, NIH HHS.
Abstract (Originalsprache)
Enzymes like peptidylarginine deiminase 4 (PAD4) generate citrullinated epitopes that are crucial in triggering and driving the anti‐citrullinated protein antibody (ACPA) response in rheumatoid arthritis. Here, we assessed whether serum PAD4‐potentiating activity is associated with subsequent arthritis development among ACPA‐positive individuals during the pre‐clinical phase. The study included 267 ACPA‐positive individuals from the Karolinska Risk‐RA cohort, among whom 101 (37.8%) developed arthritis within the observational period (range 22–60 months). We measured the ability of serum to potentiate PAD4 activity by quantifying the generation of citrullinated products using high‐performance HPLC. Study participants were then classified as PAD4 act ‐positive or ‐negative, and PAD4 status analysed in relation to onset of arthritis, clinical characteristics (ESR, CRP and DAS28) and established risk factors (HLA‐DRB genotype, smoking). PAD4 act ‐positivity was identified in 35 individuals, with a significant proportion (21, p = 0.0049) developing arthritis. Kaplan–Meier analysis demonstrated that individuals with PAD4 act ‐positivity had increased rate of progressing to arthritis ( p = 0.0022). Additionally, PAD4 act ‐positive individuals were more likely to possess at least one copy of the HLA‐DRB shared epitope allele ( p = 0.045). Notably, PAD4 act ‐positivity did not associate with pre‐clinical CRP, ESR, DAS28, or smoking status. These findings suggest that serum PAD4‐potentiating activity may help stratify arthritis risk and time to onset among ACPA‐positive at‐risk individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
- Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
- Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Małopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
- Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
- Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Region Stockholm, Sweden.
ORCID-Profile: Marta Kaminska, Aase Hensvold, Piotr Mydel
Förderung
- Narodowe Centrum Nauki
- Norges Forskningsråd
- NIH HHS
- Vetenskapsrådet
- Knut och Alice Wallenbergs Stiftelse
- King Gustaf V Foundation
- Broegelmann Foundation
- European Research Council
Zitieren
APA
Kaminska, M., Joshua, V., Bielecka, E., Kantyka, T., Chrobak, M., Lundberg, K., Hensvold, A., Potempa, J., & Mydel, P. (2026). Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population. Scandinavian Journal of Immunology, 103(5). https://doi.org/10.1111/sji.70119
Vancouver
Kaminska M, Joshua V, Bielecka E, Kantyka T, Chrobak M, Lundberg K, et al. Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population. Scandinavian Journal of Immunology. 2026;103(5). doi:10.1111/sji.70119
BibTeX
@article{Kaminska2026,
author = {Kaminska, Marta and Joshua, Vijay and Bielecka, Ewa and Kantyka, Tomasz and Chrobak, Maja and Lundberg, Karin and Hensvold, Aase and Potempa, Jan and Mydel, Piotr},
title = {Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population},
journal = {Scandinavian Journal of Immunology},
year = {2026},
volume = {103},
number = {5},
doi = {10.1111/sji.70119}
}
EUVIMED